Key result
C5a antagonist acetyl-peptide-A normalizes MAP, preserves cardiac output, and reduces inflammation in experimental cardiac tamponade.
Why the study?
Does complement C5a antagonist treatment improve acute circulatory and inflammatory consequences in a pig model of cardiac tamponade?
RCT (n=19)
randomized
Does complement C5a antagonist treatment improve acute circulatory and inflammatory consequences in a pig model of cardiac tamponade?
Complement C5a antagonism improves splanchnic macro- and microhemodynamics and reduces inflammation in an experimental pig model of cardiogenic shock induced by cardiac tamponade.
Answers are grounded in this paper and cite their sources.
C5a antagonism may improve hemodynamics in experimental tamponade; leaves open translation to human cardiogenic shock.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Érces et al. (2013) conducted an RCT in Experimental cardiac tamponade / cardiogenic shock (n=19). Complement C5a antagonist (acetyl-peptide-A) vs. Sham-operated control and untreated cardiac tamponade was evaluated on Macrohemodynamics, microhemodynamics, and inflammatory markers (superoxide, HMGB-1, big-endothelin, myeloperoxidase). Administration of the complement C5a antagonist acetyl-peptide-A normalized mean arterial pressure, preserved cardiac output, and reduced inflammatory markers in experimental cardiac tamponade.
Synapse has enriched 10 related papers. Consider them for comparative context: